<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04237610</url>
  </required_header>
  <id_info>
    <org_study_id>38RC18.171</org_study_id>
    <secondary_id>2018-A01962-53</secondary_id>
    <nct_id>NCT04237610</nct_id>
  </id_info>
  <brief_title>Reward and Punishment Sensitivity in Bipolar Disorders</brief_title>
  <acronym>Recodec-BP</acronym>
  <official_title>Reward and Punishment Sensitivity in Bipolar Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bipolar disorder (BD) represents a chronic mood disorder and one of the leading causes of&#xD;
      disability worldwide. Complexity of its clinical presentations leads to delayed diagnosis and&#xD;
      difficult management in routine clinical settings. Whereas distinguishing BD-I and BD-II main&#xD;
      subtypes has a significant relevance for treatment strategy and for outcome, there are&#xD;
      currently no clinical determinants of the BD subtype which could be used as early diagnostic&#xD;
      predictors.&#xD;
&#xD;
        -  While neurobiological specificity of each BD subtype is still controversial, available&#xD;
           evidence suggest different dopaminergic abnormalities in each subtype. Dopaminergic&#xD;
           function is involved in decision making and reward processing which may represent useful&#xD;
           BD subtype markers.&#xD;
&#xD;
        -  This study aims at assessing decision making during appetitive and punitive&#xD;
           reinforcement learning in patients with BD I and BD II subtypes compared to healthy&#xD;
           controls&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">February 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 23, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response performance in reward and loss trials</measure>
    <time_frame>one day visit</time_frame>
    <description>percentage of correct responses in the probabilistic learning task</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Bipolar disorder type I</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Bipolar disorder type II</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>behavioral assessment</intervention_name>
    <description>Probabilistic learning task</description>
    <arm_group_label>Bipolar disorder type I</arm_group_label>
    <arm_group_label>Bipolar disorder type II</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with bipolar disorder, type I and II, in a inter critical phase (euthymic period&#xD;
        defined by the mood scales scores mentioned in the inclusion criteria)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  bipolar disorder (BD) type I or II, according to DSM (Diagnostic and Statistical&#xD;
             Manual)-5 criteria&#xD;
&#xD;
          -  Montgomery and Asberg Depression Rating Scale (MADRS) score &lt; 15&#xD;
&#xD;
          -  Young Mania Rating Scale (YMRS) score &lt; 12&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other main diagnosis than bipolar disorder&#xD;
&#xD;
          -  other medical condition leading to cognitive deterioration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mircea POLOSAN, MD, PhD</last_name>
    <phone>0033476765414</phone>
    <email>mpolosan@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arnaud POUCHON, MD</last_name>
    <email>apouchon@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Grenoble Alpes</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Polosan Mircea</last_name>
      <phone>0033476765414</phone>
      <email>mpolosan@chu-grenoble.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 10, 2020</study_first_submitted>
  <study_first_submitted_qc>January 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>reinforcement learning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

